Interestingly, a recent study showed that the persistence of anti-tumor CD4+ T cells is critical for effective PD-1 and CTLA4-based cancer immunotherapies in elderly mice, as correcting DCs’ migratory defects in the elderly induced Th1 CD4+ T cells with cytolytic activity that drive anti-tumor immunity (72). This evidence concerns the gene CD4 and neoplasm.